55
Saturday, October the 10, 2015 Culture of Quality Opening Note and Programme overview Full day workshop Drugs Regulatory Authority of Pakistan Habib University, Karachi Obaid Ali & Roohi B. Obaid Civil Service Officers/ Deputy Director

2 of 5 Overview by Obaid Ali

Embed Size (px)

Citation preview

Page 1: 2 of 5 Overview by Obaid Ali

Saturday, October the 10, 2015

Culture of QualityOpening Note and Programme overview

Full day workshop

Drugs Regulatory Authority of Pakistan

Habib University, Karachi

Obaid Ali & Roohi B. ObaidCivil Service Officers/ Deputy Director

Page 2: 2 of 5 Overview by Obaid Ali

Not the view of DRAP

Current judgment of speaker

No obligation on DRAP

Regulatory experience

It has nothing to do with any

specific commercial

product

It is just a knowledge

sharing exercise nothing more than

that

DISCLAI

MER

Page 3: 2 of 5 Overview by Obaid Ali

About Half a billion population died

4Lakh per year in Europe

Page 4: 2 of 5 Overview by Obaid Ali

Small pox Plague Meningitis Tuberculosis

Heart Attack Infections Psychiatry Diabetes

Page 5: 2 of 5 Overview by Obaid Ali

Hepatitis Ebola

Page 6: 2 of 5 Overview by Obaid Ali

Who Cares?

It is Pharmaceutical Industry … Science … Research ..

Page 7: 2 of 5 Overview by Obaid Ali

Pharmaceutical Companies

Regulatory Agencies

Page 8: 2 of 5 Overview by Obaid Ali

Very near to your and your beloved one’s lives

Page 9: 2 of 5 Overview by Obaid Ali
Page 10: 2 of 5 Overview by Obaid Ali

Drug Safety from Pre Market to Post Market"DO YOU KNOW IN 2008 ....., used to stop

bleeding during open heart surgery killed a lot of patients.

The lives of 22,000 patients in USA alone could have been saved if U.S. regulators had

been quicker to ban it. The same was extensively used in Pakistan too but no body

knows, it killed how many in our country

Page 11: 2 of 5 Overview by Obaid Ali

2008?

Page 12: 2 of 5 Overview by Obaid Ali

Over sulfated chondroitin sulfate (OSCS)

Page 13: 2 of 5 Overview by Obaid Ali

149 deaths

Test was passed

Signals not responded

Finally contamination

detected

Let’s think together

Page 14: 2 of 5 Overview by Obaid Ali

If it happened in Pakistan, were me & you able to catch?

What do you think can it be caught in testing?

Do you think we are capable to catch such level of contaminant or less?

No

YesDon’t know

Page 15: 2 of 5 Overview by Obaid Ali

100’s of

Deaths

Page 16: 2 of 5 Overview by Obaid Ali

2001-2005750m $ Mix up Too much or too

little API Contamination

A number of products, tablet, cream, comtrol release etc.

Page 17: 2 of 5 Overview by Obaid Ali

Regulations

EnforcementCompliance

Guarantee

?

Page 18: 2 of 5 Overview by Obaid Ali

1

2 3

4

Let’s identify attribute of culture

Page 19: 2 of 5 Overview by Obaid Ali

Let’s identify correct relationship

Girl and Mehndi

Boys and Mehndi

Girl and Tattos

Page 20: 2 of 5 Overview by Obaid Ali

Let’s identify correct relationship

Mehndi & Bangles

Boys and Bangles

Girl and Bangles

Page 21: 2 of 5 Overview by Obaid Ali

Let’s identify correct relationship

Eid

Exam day

Fun

Page 22: 2 of 5 Overview by Obaid Ali

A normal brain irrationally puts more weight on a small loss than big one or

sometimes a huge opportunity

Page 23: 2 of 5 Overview by Obaid Ali

TOOL

Approach

Stan

dard

Page 24: 2 of 5 Overview by Obaid Ali
Page 25: 2 of 5 Overview by Obaid Ali
Page 26: 2 of 5 Overview by Obaid Ali

Sorry for broken trust … ... I am endlessly sorry

Martin Winterkorn

4,82, 000 cars … > 18 billion USD fine………..

Sep 20, 2015

Page 27: 2 of 5 Overview by Obaid Ali

Hiding an alleged link b/w Pioglitazone & bladder cancer

Emails raising concern about the issue were deleted

Page 28: 2 of 5 Overview by Obaid Ali

9 billion USD penalty2014

Page 29: 2 of 5 Overview by Obaid Ali

Clinical Trial

2000 for HTN

Further trials for stroke & angina

EmployeesParticipatio

n

CoI not reported

Employees in data

analysis

Manipulation in

scientific reports

Data fabrication Reported

Retraction of several

papersPublicly

apologized

Page 30: 2 of 5 Overview by Obaid Ali

2014-2015Got temporary suspension of

business

Reputational hit Data tempering

False advertisingData hiding Ends up with sorry

Page 31: 2 of 5 Overview by Obaid Ali
Page 32: 2 of 5 Overview by Obaid Ali

1999 100 M2002 30 M2002 500 M2010 750 M

GMP

Page 33: 2 of 5 Overview by Obaid Ali

• Off-label use promotion

P

USA • 0.43 billion USD fine

2004

Page 34: 2 of 5 Overview by Obaid Ali

• Fraud

M

• Kick-backs

USA • 0.95 billion USD fine

2008

Page 35: 2 of 5 Overview by Obaid Ali

• Off-label use promotion

P

• Kick-backs

USA • 2.3 billion USD fine

2009

Page 36: 2 of 5 Overview by Obaid Ali

• Off-label use promotion

L

USA • 1.4 billion USD fine

2009

Page 37: 2 of 5 Overview by Obaid Ali

• Off-label use promotion

AG

USA • 0.60 billion USD fine

2010

Page 38: 2 of 5 Overview by Obaid Ali

• Off-label use promotion

AZ

• Kick-backs

USA • 0.52 billion USD fine

2010

Page 39: 2 of 5 Overview by Obaid Ali

• Off-label use promotion

N

• Kick-backs

USA • 0.423 billion USD fine

2010

Page 40: 2 of 5 Overview by Obaid Ali

• Failure to disclose safety data

• Off-label use promotion

G

• Paying kick-back• Making false

misleading statements

USA • 3 billion USD fine• Criminal & civil

fine

2012

Page 41: 2 of 5 Overview by Obaid Ali

• Off-label use promotion

AT

USA • 1.9 billion USD fine

2012

Page 42: 2 of 5 Overview by Obaid Ali

• Off-label use promotion

J

• Kick-backs

USA • 2.2 billion USD fine

2013

Page 43: 2 of 5 Overview by Obaid Ali

Recognition

• Publicly recognizing the gravity of the crisis

Responsibility

• Leaders taking personal responsibility to manage the crisis

Regret

• Expressing deep regret on behalf of company

Remedy

• Outline the steps going & continue to take to address the situation

Sorrythe worst nightmare

Page 44: 2 of 5 Overview by Obaid Ali

Mal-practices in drug manufacturing

Regulations came into force

Tragedies occurred

Regulations continue to be stringent & complex

Historical Perspective

Page 45: 2 of 5 Overview by Obaid Ali

PHARMACEUTICALSA Business driven Profession

Page 46: 2 of 5 Overview by Obaid Ali

New

To

ols

Approaches

Stan

dard

sE

Q

P

S

REGULATORY

SCIENCE

Page 47: 2 of 5 Overview by Obaid Ali

Innovation

Science

Page 48: 2 of 5 Overview by Obaid Ali

Need justifies Outcome

RiskBenefit

Page 49: 2 of 5 Overview by Obaid Ali

Reasonable Safety is required

Page 50: 2 of 5 Overview by Obaid Ali

Do you calculate a cost of poor quality at your site?

Page 51: 2 of 5 Overview by Obaid Ali

Do you calculate a cost ofimproving quality versus failure?

Page 52: 2 of 5 Overview by Obaid Ali

Science

Rational

QUALITY

METRICS

Page 53: 2 of 5 Overview by Obaid Ali

Econometrics

Pharmacometrics

Chemometrics

Science

Rational

Page 54: 2 of 5 Overview by Obaid Ali

Quality Metrics & Case Studies will be discussed

in next talk

Page 55: 2 of 5 Overview by Obaid Ali

Thank you of your attention